Rosetta and NYU expand microRNA collaboration

Israel-Rosetta Genomics Ltd. and the New York University School of Medicine have expanded their collaboration to include congenital heart disease.

REHOVOT, Israel-Rosetta Genomics Ltd. and the New York University School of Medicine have expanded their collaboration to include congenital heart disease. Applying Rosetta Genomics' microRNA extraction protocols from various body fluids and NYU School of Medicine's experience in this field, they will screen for specific microRNA biomarkers and signatures that may be used to diagnose and target congenital heart disease in newborns. "As a cutting-edge research institution, NYU School of Medicine is a close collaborator of Rosetta Genomics in the microRNA field, and I am confident this collaboration will enhance our understanding of the link between microRNAs and various heart conditions," notes Amir Avniel, CEO and president of Rosetta Genomics.


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Front Cover

Latest Issue  

• Volume 18 • Issue 12 • December 2022/January 2023

December 2022/January 2023

December 2022/January 2023 issue